Cargando…
Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth
PURPOSE: Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there...
Autores principales: | Lee, Jaehyun, Shin, Yong Jae, Lee, Kyoungmin, Cho, Hee Jin, Sa, Jason K., Lee, Sang-Yun, Kim, Seok-Hyung, Lee, Jeongwu, Yoon, Yeup, Nam, Do-Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056981/ https://www.ncbi.nlm.nih.gov/pubmed/29129044 http://dx.doi.org/10.4143/crt.2017.315 |
Ejemplares similares
-
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling
por: Lee, Jin-Ku, et al.
Publicado: (2014) -
In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma
por: Sa, Jason K., et al.
Publicado: (2015) -
Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain
por: Park, Hyunkyu, et al.
Publicado: (2017) -
Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme
por: Kang, Wonyoung, et al.
Publicado: (2015) -
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
por: Nam, Yoonhee, et al.
Publicado: (2023)